*Tail, you're imbecile, not a single iota of your idiotic rhetoric has come to fruition except for the PDUFA delay. Good call on that but you're still an idiot.
No, absolutely zero probability. Any new application would require studies and formal FDA submission. This would all be well documented.
Just posting facts and my opinion that this is under-perform. Coincidentally, Goldman Sach's also issued an under-perform rating on NPSP yesterday.
Opened red, lgonber. FYI, I was not in the FDA group that delayed rhpt1-84. I'm just a guy who figured it out. Take your issues up with NPS management.
*$27.55pps. ce527, I wish you the best of luck in your trading/investing and great health in life. Speaking of health, time for the Facebook CC.
This movement is minimal only 1-3% range. Interesting that the pps is positive after such a negative catalyst. This is counter-intuitive and an anomaly. Volume has been, particularly low, the last two sessions. The morning has brought institutional sales visualized in the early drops followed by retail purchases throughout the remainder of the trading day. The buying has been almost completely small retail buys. NPSP continues to have significantly below sector average fundamentals and just a had a major negative catalyst in the PDUFA delay. I reaffirm my under-perform rating.
That's a massive drop in pps or massive dilution or both. Learn how to read fundamentals before you come out guns blazing firing blanks.
Opposite position, this will drop continuously for the next several months. There will be a second delay as the REMS are clarified with an increased probability of CRL. The FDA wanted to CRL rhpt1-84 but because of the orphan status instead applied heavy REMS and a 3 month delay. In addition, I believe this second delay will be accompanied by a secondary offering (dilution) from NPSP.
The buyout rumor was nothing but a rumor and that euphoria will wane with every passing day. The p/e of 1337 is grossly above sector average and the Q3 report will confirm these poor fundamentals causing additional downward pressure.
I originally shorted NPSP as a trade but after extensive due diligence have settled in for a longer term perspective with no intention to cover in the next 3-6 months.
If GoPro traded at the same p/e as it's closest competition, Sony, it would trade @ about $29pps. Basic mathematics. Sony, also has ps4, 3D tvs, top line headphones, top line speakers, blu-ray players etc. In reality, GoPro will trade under $10pps, and possibly below $5pps, if it does not monetize viral content.